Financing led by Novo Holdings with significant support from world-class group of existing and new investors  Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated precision immunology pipeline    Newton, MA & Wädenswil, Switzerland – May 27, 2025– GlycoEra AG, a...